Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus Price Target from Analysts

by · The Cerbat Gem

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) have received a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $23.67.

Several research firms recently weighed in on ACRV. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 price objective on shares of Acrivon Therapeutics in a research report on Monday, September 16th. Piper Sandler Companies reaffirmed a “buy” rating and set a $30.00 price target on shares of Acrivon Therapeutics in a report on Friday, September 6th. BMO Capital Markets decreased their price objective on shares of Acrivon Therapeutics from $28.00 to $27.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. LADENBURG THALM/SH SH raised Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Monday, September 16th. Finally, HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Acrivon Therapeutics in a research report on Thursday, November 14th.

View Our Latest Stock Analysis on ACRV

Acrivon Therapeutics Price Performance

Shares of NASDAQ ACRV opened at $5.41 on Thursday. The business has a fifty day moving average price of $7.31 and a two-hundred day moving average price of $7.50. The stock has a market capitalization of $168.45 million, a PE ratio of -2.00 and a beta of 0.55. Acrivon Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $11.90.

Hedge Funds Weigh In On Acrivon Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP acquired a new stake in shares of Acrivon Therapeutics during the second quarter valued at about $58,000. XTX Topco Ltd acquired a new stake in Acrivon Therapeutics during the 2nd quarter worth approximately $61,000. Rhumbline Advisers grew its holdings in Acrivon Therapeutics by 48.9% during the 2nd quarter. Rhumbline Advisers now owns 16,209 shares of the company’s stock worth $94,000 after acquiring an additional 5,320 shares during the last quarter. Bank of New York Mellon Corp increased its position in Acrivon Therapeutics by 50.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 36,632 shares of the company’s stock valued at $212,000 after acquiring an additional 12,219 shares during the period. Finally, Barclays PLC raised its stake in shares of Acrivon Therapeutics by 51.2% during the third quarter. Barclays PLC now owns 33,306 shares of the company’s stock valued at $233,000 after acquiring an additional 11,273 shares during the last quarter. Institutional investors and hedge funds own 71.62% of the company’s stock.

About Acrivon Therapeutics

(Get Free Report

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

See Also